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Abstract
PtII azido complexes [Pt(bpy)(N3)2] (1), [Pt(phen)(N3)2] (2) and trans-[Pt(N3)2(py)2] (3)
incorporating the bidentate diimine ligands 2,2′-bipyridine (bpy), 1,10-phenanthroline (phen) or
the monodentate pyridine (py) respectively, have been synthesised from their chlorido precursors
and characterised by x-ray crystallography; complex 3 shows significant deviation from square-
planar geometry (N3–Pt–N3 angle 146.7°) as a result of steric congestion at the Pt centre. The
novel PtIV complexes trans, cis-[Pt(bpy)(OAc)2(N3)2] (4), trans, cis-[Pt(phen)(OAc)2(N3)2] (5),
trans, trans, trans-[Pt(OAc)2(N3)2(py)2] (6), were obtained from 1–3 via oxidation with H2O2 in
acetic acid followed by reaction of the intermediate with acetic anhydride. Complexes 4–6 exhibit
interesting structural and photochemical properties that were studied by x-ray, NMR and UV-vis
spectroscopy and TDDFT. These PtIV complexes exhibit greater absorption at longer wavelengths
(ε = 9756 M−1cm−1 at 315 nm for 4; ε = 796 M−1cm−1 at 352 nm for 5; ε = 16900 M−1cm−1 at
307 nm for 6, in aqueous solution) than previously reported PtIV azide complexes, due to the
presence of aromatic amines, and 4–6 undergo photoactivation with both UVA (365 nm) and
visible green light (514 nm). The UV-vis spectra of complexes 4–6 were calculated using TD-
DFT; the nature of the transitions contributing to the UV-vis bands provide insight into the
mechanism of production of the observed photoproducts. The UV-vis spectra of 1–3 were also
simulated by computational methods and comparison between PtII and PtIV electronic and
structural properties allowed further elucidation of the photochemistry of 4–6.
Introduction
PtII pyridyl compounds are well-known to exhibit a rich photochemistry, which can be tuned
through peripheral modification of the ligands bound to the PtII centre.1,2 The low energy
spectroscopic absorption band in the visible region and long-lived excited states of these
complexes lead to a variety of applications, including their use in biosensors,3 light-emitting
devices4 and dye-sensitised solar cells.5 The biological properties of PtII amines have been
extensively investigated, with particular emphasis on potential antitumor activity following
the success in the clinic of the PtII drug cisplatin, cis-[Pt(NH3)2Cl2], and related complexes.6
PtIV complexes are much more inert to reaction than PtII species, and tuning their reactivity
to achieve selective reduction to PtII in vivo provides a strategy for reducing the side-
†Electronic Supplementary Information (ESI) is available: Crystallographic data for compounds 1–6, Ortep plots of 1 and 2, mass
spectrometric data and TDDFT singlet excited-state data. CCDC numbers 709182 (2), 709183 (1), 709184 (3), 709185 (4), 709186
(5), 709187 (6) relate to the crystallographic data for this paper. These data can be obtained free of charge from The Cambridge
Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif
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reactions associated with PtII antitumor drugs.7,8 Although reports of PtIV bipyridine
complexes, for example, have been largely structural,9 Lippert and co-workers have
investigated the photoreduction of trans-[Pt(bpy)(MeNH2)2(OH)2]Cl2; after irradiation for
several days (dose not stated), free MeNH3+ was detected, indicating that amine dissociation
had occured.7,10
Photoactivation of metal complexes can be used for triggering specific interactions between
the metal complex and target macromolecules of biological relevance (such as DNA, RNA
or proteins).11 Upon irradiation, photoactivable metal complexes can undergo ligand
dissociation from the excited state, forming labile solvated species that are more reactive
towards the target macromolecule.12 Light activation offers the advantage of temporal- and
spatial-control of the active species in tissues, potentially reducing undesired secondary
effects due to the toxicity of such species. It is notable that several complexes of d8 metal
ions with α-diimine ligands have been reported to photosensitise the production of singlet
oxygen (1O2)13-15 and so there is scope for the use of photoactivatable metal complexes in
photodynamic therapy16 and for virucidal applications.17,18
The efficacy of photoactivatable metal complexes as potential anticancer agents depends
strongly on their excited-state properties. The relative energies of singlet and triplet excited
states influence the choice of the excitation wavelength, and determine the nature of the
photoproducts, their mechanism of formation and the yield of ligand photodissociation.19
Density functional theory (DFT) and time-dependent DFT (TDDFT) are fundamental tools
for rational design of metal-based drugs with tunable properties, since they can provide a
description of electronic structures and excited states of metal complexes.20
Our recent approach has been to develop PtIV complexes which can be reduced to cytotoxic
PtII by photoactivation, selectively at a tumour site.21,22,23,24 For effective
photochemotherapy of non-surface tumours it is desirable to activate complexes with
relatively long wavelengths of light since the penetration of light into tissue is wavelength-
dependent.25 Furthermore, the use of visible light is less likely to cause damage of biological
tissue.25c,26 Current photochemotherapy typically employs red light (~ 620 nm) which is
suitable for activation of established photodynamic agents.27 We are therefore investigating
methods to achieve photoactivation of PtIV-azido complexes at a variety of wavelengths.
Here we describe the synthesis and characterisation of new PtIV azido complexes 4–6 and
their synthetic PtII precursors 1–3 (Figure 1); although complexes 1 and 2 have been
previously reported18,28 we present here further characterisation, including x-ray
crystallographic structures.
Results
Dichlorido PtII compounds [Pt(bpy)Cl2], [Pt(phen)Cl2] and trans-[PtCl2(py)2] were prepared
by literature methods.29,30 The chloride ligands were then substituted by azido ligands by
stirring the complexes with an excess of sodium azide in DMF. The reaction of complexes
1–3 with H2O2 in acetic acid resulted in oxidation.31,32 The main products in all three cases
were the monohydroxido, monoacetato species [Pt(L)(N3)2(OAc)(OH)] (L = bpy, phen,
(py)2), which were then readily converted to the diacetato complexes 4–6 by stirring in
acetic anhydride.
Crystal Structures
Square-planar PtII bipyridine and phenanthroline complexes (1 and 2) both crystallised in a
monoclinic crystal system. In both systems deviation from square-planar geometry is
observed; the angle(s) which the platinum azide group Pt-Nα makes with the plane defined
by N(ring)-Pt-N(ring) is 1.54 ° for 1 (which contains a two-fold axis of symmetry) and 3.02 °
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and 2.24 ° for 2. For 1, angles at the coordinated azide group (Pt–Nα–Nβ) are 119.3(2)° with
Pt–Nα and Pt–N(ring) bond lengths of 2.034(3) Å and 2.008(3) Å, respectively. For 2, angles
at the coordinated azide group are 121.8(4)° and 125.1(4)° with Pt–Nα bond lengths of
2.022(6) Å and 2.037(5) Å and Pt–N(ring) lengths of 2.011(6) Å and 2.011(5) Å,
respectively. Complex 3 also crystallised in a monoclinic crystal system containing a two-
fold axis of symmetry. The geometry around the platinum centre is significantly distorted
from square-planar geometry and the pyridine rings demonstrate positional disorder. The
pyridine ring is disordered approximately equally over two orientations. The two
components were restrained to have similar bond distances and angles. For 3, angles at the
coordinated azide group (Pt–Nα–Nβ) are 125.4(5)° with Nα–Pt–Nα angles and Pt–Nα bond
lengths of 146.7(4)° and 2.036(7) Å respectively. For the structures and crystallographic
parameters of 1, 2 and 3 see Figure S1 and Table 1 respectively.
Each of the PtIV complexes (4–6) crystallised in a different crystal system and space group,
however they all contain a two-fold axis of symmetry (Figure 2) and adopt approximate
octahedral geometry; the O–Pt–O angles are 179.18(14)° (4), 165.12(19)° (5) and 179.994°
(6). The Pt–Nα distances are 2.022(3) Å, 2.032(4) Å and 2.049(6) Å respectively, and the
Pt–N(ring) distances 2.033(3) Å, 2.052(4) Å and 2.028(6) Å, respectively. The angles at the
coordinated azide groups are 115.0(3)°, 118.5(4)° and 114.9(5)°, respectively. The
crystallographic parameters are given in Table 1 and a selection of key bond lengths and
angles are shown in Table 2.
In general, the structures optimized by DFT calculations are in good agreement with those
obtained from X-ray crystallography. DFT tended to overestimate bond lengths of 1–6,
particularly in the case of Pt–N (bpy, phen, py) where distances are up to 0.06 Å longer. In
the case of complexes 1 and 2, the Pt–Na1 and Pt–Nα2 bond lengths are underestimated.
Optimising the geometry in the gas phase rather than the condensed phase is a possible
source of this inconsistency33 although recent results suggest that this is unlikely to
significantly affect the values34. DFT-calculated angles are within a few degrees of the X-
ray values; the only exception being the angles relating to the azide ligands; for all
complexes, X-ray and DFT gave differences in the orientation of the N3 groups although this
is unlikely to be energetically significant. Data are summarized in the Supplementary
Information (Tables S1–4).
Orbital Analysis
The PtIV complexes 4 (bpy) and 5 (phen) have similar frontier orbitals, those of 4 are shown
in Figure 3. The HOMOs of 4 and 5 are mainly azide-based, with a small contribution from
Pt. The HOMO shows a bonding interaction between the two azide Nα atoms, while it is
antibonding with respect to the Nα-Nβ and Pt-Nα bonds. The HOMO–1 is similar in shape
to the HOMO, while the HOMO–2 is more diffuse, having contributions also from the
acetate groups and the chelating ligand. The LUMO and LUMO+1 of 4 and 5 are strongly
antibonding orbitals; the LUMO is antibonding towards the Pt–N(azide) and Pt–N(bpy,
phen) bonds, LUMO+1 is antibonding towards Pt–N(azide) and Pt–O(Ac) bonds. Higher in
energy, the LUMO+2, LUMO+3 and LUMO+4 are all bpy- or phen-based. In complex 6 the
HOMO is azide-centred. In the HOMO–1 and HOMO–2 the acetate character progressively
increases, and the HOMO–3 is mainly acetate-based. In 6, the LUMO has antibonding
character for the Pt–N(azide) bonds, while the LUMO+1 is antibonding towards both acetate
and azide ligands. Both the LUMO+2 and LUMO+3 are py-centred.
The PtII complexes show similar features in the frontier orbitals which play a significant role
in the UV-vis spectra. However, there is a major and fundamental difference in the
unoccupied orbitals. The LUMO and LUMO+1 of 1 and 2 are bpy- or phen-based π*
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orbitals, those of 1 are shown in Figure 3. The lowest-energy antibonding orbital is LUMO
+2 which lies ca.1 eV above LUMO+1. Complex 3 has orbitals that resemble those of 6,
differing in that the LUMO has lost its antibonding character and the other empty orbitals
are of higher energy.
UV-vis spectroscopy and TD-DFT singlet transitions
Computed UV-vis spectra of complexes 1 and 2 were in agreement with previously
published data.18 Theoretical UV-vis spectra of 4–6 were calculated by TD-DFT with the
CPCM solvent model and then overlaid with the experimental spectra which were recorded
in water (Figure 4). The most representative electron density difference maps for the singlet
transitions of 4–6 are also reported in Figure 4. Experimental and theoretical data are
summarized in Tables 3-5.
Complex 4 shows a maximum at 250 nm and a pronounced shoulder around 310 nm; a weak
absorbance is also present at ca. 350 nm. Similarly, the main absorbance of 5 is at 272 nm
and a shoulder, although significantly less pronounced, is visible at 300 nm. In addition, 5
has two weak bands in the range 330–360 nm. TD-DFT calculations performed without
relativistic correction give satisfactory results in the case of 5, despite a small red shift in the
absorbance energies. On the contrary, less satisfactory is the determination of the 310-nm
band intensity for 4. However, the general character of the electronic transitions of 4 was
confirmed by performing calculations with different software (see Computational Details
and Supplementary Information). For both complexes, the lowest-energy absorbance is due
to ligand-to-metal charge transfer (LMCT)23 states (state S6 for both 4 and 5), where
electron density migrates from the acetate groups to the metal. At higher energy, the
transitions composing the shoulder are a mixture of LMCT (N3 → Pt) and ligand-to-ligand
charge-transfer states (LLCT, N3 → bpy, phen). LMCTs are predominant in 4, while LLCTs
are predominant in 5. The highest-energy bands are of mixed character in both complexes,
and bpy and phen have marginal roles.
For complex 6, the band centred at 304 nm has an almost pure LMCT (py → Pt,N3)
character.35 TDDFT assigns the band at 260 nm to LLCT transitions (OAc → py), but
underestimates their oscillator strength values. The λmax of complex 6 is shifted towards the
red region compared to complexes 4 and 5 which is due to the trans geometry of the azide
ligands.36
Photochemistry of 4–6
Aqueous solutions of platinum (IV) complexes 4–6 (ca. 50 μM) were irradiated with UVA
light (power ca. 1.5 mW/cm2), and UV-visible spectra were recorded after 0, 1, 5, 15, 30 and
60 min of irradiation (see Figure 5). Marked changes in the spectra occurred following
irradiation. For 4 and 5, a large and weak band appeared at ca. 370 nm corresponding to
formation of PtII species,18 and a decrease in the UV band at ca. 250 nm was observed.
Complex 6 behaved slightly differently since no absorption appeared at wavelengths longer
than 350 nm upon irradiation, with a new band appearing at 250 nm while at 300 nm there
was a significant decrease in absorbance. The pH of the non-buffered aqueous solutions of
4, 5 and 6 after 2h UVA irradiation did not increase. Following irradiation of 6, ESI-MS
analysis (positive ion mode) showed peaks corresponding to [Pt(OH)2(py)2 + H]+ (obs:
388.4 m/z, calc: 388.1 m/z) and its fragment [Pt(OH)(py)2]+ (obs: 370.4 m/z, calc: 371.1 m/
z) (see Figure S2).
Photoactivation studies of complexes 4–6 using visible (green) light (514 nm, 60 mW/cm2)
were carried out on 1 mM 90% D2O / 10% d6-acetone solutions, acetone being used to aid
dissolution. 1H NMR spectra were recorded after 0, 15, 30 and 60 min irradiation. Changes
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in the spectra for 4–6 were observed following irradiation with the acetate region providing
the clearest picture of speciation; as judged by the free and bound acetate resonances (Figure
6). Complex 6 gave rise to free acetate the fastest, with ca. 85% reacting after only 15 min of
irradiation, and after 30 min only a very small peak corresponding to bound acetate was
visible. In contrast, only half of complexes 4 and 5 had reacted after 30 min, and after 60
min ca. 40% of each of the original compounds remained.
Discussion
The standard protocol of using an aqueous solution of silver nitrate to remove chlorides
from a PtII centre to produce reactive aqua adducts reportedly produces oxygen-bridged
dimers when ligands such as bipyridine or phenanthroline are present.37 For this reason we
employed the method of direct substitution of chloride by azide in DMF. Problems were
encountered while attempting to oxidise the PtII complexes 1–3 by the method previously
used to generate PtIV azides (H2O2 added to an aqueous suspension of the PtII diazide
species)21,36,38 since complexes 1–3 required harsher conditions to undergo oxidation. The
use of acetic acid followed by acetic anhydride allowed us to oxidise these complexes and to
synthesise the diacetato PtIV products 4–6 in good yield.
Although there are many examples of PtIV bipyridine and phenanthroline compounds with
halide or alkyl ligands39 complexes 4–6 appear to be the first reported PtIV pyridine,
phenanthroline and bis-pyridine azido complexes. The oxidation of the PtII-azido precursors
is hindered by their sensitivity to both heat and light. In contrast, compounds such as
[Pt(L)R2] (L = bpy, phen; R = alkyl, aryl) are easily oxidised by H2O2,39g,h indeed such
reactions are reported to proceed rapidly at room temperature. Ligands such as methyl form
strong σ-bonds to PtII, raising the energy of the HOMO and thereby making the PtII species
more susceptible to oxidation.39h Oxidation of halogen-containing complexes [Pt(L)X2] (X
= Cl, Br, I) with H2O2 is much more difficult due to the greater ionic component in Pt–X
bonds and the resultant reduced donation of charge to the metal centre. Halido PtIV α-
diimine complexes have been produced by using oxidants such as Cl2, Br2 and/or more
forcing conditions (e.g. high temperature or photocatalysis).39d-f,i None of these synthetic
routes are suitable for oxidising [PtII(L)(N3)2] (L = bpy, phen) diazido complexes to a PtIV
complex with oxygen bound in axial positions. The preference for groups such as OH or
OCOCH3 in the axial positions arises from their stabilising effect on PtIV, which is a
desirable feature for potential photoactivatable prodrugs since compounds containing axial
chloride ligands are often readily reduced in vivo without irradiation.10
The oxidation route we employed to synthesize the diacetato complexes, which proceeds via
initial formation of the monohydroxido monoacetato species [Pt(L)(N3)2(OAc)(OH)] (L =
bpy, phen, (py)2) in H2O/acetic acid, is anticipated to occur with retention of the OH oxygen
in the second step, in accordance with the literature.40 The oxidation step may proceed
directly to the mixed OH/OAc complex with participation from the acetate anion41 or via a
dihydroxido species, followed by nucleophilic substitution of the acetate. If the oxidation
occurs via the latter mechanism, the first step in the substitution is anticipated to be
protonation of OH. Since only the monosubsituted species [Pt(L)(N3)2(OAc)(OH)] is
isolated, this would imply that the pKaH of the second axial hydroxido is lower than the pKa
of acetic acid (4.75).42
Crystal structures and DFT electrostatic potentials
The bond lengths and angles of complexes 1 and 2 (Tables S1 and S2) are comparable to
similar reported structures.43,44 For a discussion of the crystal packing of 1 see the
supporting information.
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Complex 3 shows a significant distortion from square-planar geometry which can be
attributed to steric interactions between the azide ligands and the pyridine rings. Deviations
from square planar towards tetrahedral geometry are common for PtII complexes containing
bulky or rigid ligands.45,46 Complex 3 is symmetrical with regard to the azido ligands, the
bond lengths within the azido groups are consistent with those found in other azido
compounds.47,48
The azide bond lengths and angles for complexes 4–6 (Table 2) compare well with other
platinum azide structures.36 The Pt–N(ring) bond lengths of 4–6 are ca. 0.02–0.04 Å longer
than those of the corresponding PtII compounds (1–3); a difference which has also been
reported for [PtIV(bpy)Cl4]9d and [PtII(bpy)Cl2].44
Distortion from ideal octahedral geometry occurs in all three PtIV structures (4–6). The axial
Pt–O(acetate) bonds are bent with respect to the plane formed by the equatorial ligands in 4
and 5, possibly to minimise intramolecular repulsions; the bending of the axial acetate bond
in similar PtIV complexes has been attributed to intramolecular hydrogen bonding.49,50 The
restricted bites of the chelating bipyridine and phenanthroline ligands (ca. 80°) in 4 and 5
also cause distortion. Complexes 4–6 contain intermolecular hydrogen-bonded networks,
and some weak π-π stacking exists between molecules of complex 5. Interestingly, complex
4 shows a weak AcO⋯H–C(bpy) interaction which is not present in 5, where acetate groups
are interacting with the π electrons of the phen ligand. Figure 7 shows the changes in the
electrostatic potential surfaces of 2 and 5 due to such an interaction.
Photochemistry and TD-DFT
The photoreactions of PtIV azide complexes are of interest due to the potential use of such
complexes as photoactivated anticancer agents.36
Absence of isosbestic points indicates that more than one photoproduct is obtained by
irradiation. According to calculations and experimental work done on similar systems,51 it is
reasonable to assume that both azide and acetate ligands can easily be displaced by solvent
molecules upon irradiation. In fact, the strongly antibonding character of LUMO and LUMO
+1 suggests that all the transitions having contributions from such orbitals are dissociative.
As shown in Figure 6, formation of free acetate in irradiated samples can be easily
monitored by 1H NMR. Furthermore, ligand dissociation can be confidently associated with
reduction of PtIV to PtII, consistent with the appearance of the MLCT-like absorption at 370
nm (for 4 and 5) and the reported behaviour of [PtIV(bpy)Cl4].39c
The UV-vis spectra of complexes 4 and 5 after 2 h UVA irradiation were remarkably similar
to those reported52 for [Pt(L)(OH)2] and [{Pt(L)(μ-OH)}2] (L = bpy, phen) suggesting that
these were significant photoproducts. ESI-MS of irradiated solutions of 6 revealed that the
py ligands can be retained as the acetate is lost, with species such as [Pt(OH)2(py)2 + H]+
detected (Figure S2); such aqua adducts would be effective for DNA binding if
photoactivation is carried out in vivo. No dimers were observed, perhaps hindered by the
trans geometry.
The lack of increase in pH of the solutions of 4–6 after 2 h UVA irradiation is in contrast to
solutions of analogous PtIV-azido compounds containing NH3 ligands for which a sharp
increase in pH to >10 was seen under similar conditions.51 We suggest that this is because
continued irradiation of the NH3-containing complexes results in release of the coordinated
ammine; it is not clear whether bpy, phen and py are released on continued irradiation, but
they are significantly less basic thanNH3.
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Complexes 4–6 underwent photoreaction with green light (514 nm) giving rise to free
acetate. Although the 1H NMR spectra of 4 clearly show an NMR peak for the released
acetate, irradiation of 5 and 6 produced more complicated spectra, possibly due to formation
of significant mono-acetato Pt intermediates or through weak electrostatic interactions of the
free acetate with the photoproducts. Although the absorbance in the UV-vis spectrum at 514
nm for all three complexes is very low, the photodissociative behaviour may be explained by
the computed singlet transitions in Table 6. Low-energy transitions of a highly dissociative
nature exist for complexes 4–6 (all involving LUMO and LUMO+1) despite the very small
oscillator strengths; excitation of these transitions with green light can evidently still
produce ligand dissociation.
Experimental
Methods and Materials
Materials—Silver nitrate, pyridine (py), d6-acetone, d6-DMSO, D2O and 1,4-dioxane were
purchased from Aldrich, NaN3, HCl (37%), acetic anhydride and acetic acid (> 99%) from
Fisher, H2O2 and 1,10-phenanthroline (phen) from Sigma, K2[PtCl4] from Alfa Aesar, and
2,2′-bipyridine (bpy) from Acros.
NMR Spectroscopy—NMR spectra were recorded at 298 K on a Bruker DMX500 (1H:
500.13 MHz) magnet. Samples were prepared in d6-acetone, d6-DMSO, D2O or 90% H2O /
10% D2O with 1H chemical shifts referenced internally to dioxane (δ 3.75 ppm in D2O; δ
3.764 ppm for 90% H2O / 10% D2O). All data were processed with XWIN-NMR software
(Version 3.6, Bruker, UK Ltd.). All J values are quoted in Hz.
Mass Spectrometry—Positive ion electrospray mass spectrometry (ESI-MS) was
performed on a Platform II Mass Spectrometer (Micromass, Manchester, UK). The capillary
voltage was 3.5 V and the cone voltage typically varied between 5 and 30 V. The source
temperature was adjusted depending on the solvent. Data were acquired and processed with
Mass Lynx (Version 2.0) software.
UV-visible Spectroscopy—UV-visible electronic absorption spectra were recorded on a
Varian Cary 300 UV-visible spectrophotometer in 1-cm path-length cuvettes. Data were
processed with Microcal Origin 5.0.
Light Sources—The ultraviolet light source used for photochemical studies was a
broadband UVA lamp (2 × 15 W tubes, model VL-215L; Merck Eurolab, Poole, UK) which
operated with a maximum output at 365 nm. Samples were irradiated at a distance of 10 cm
from the lamp, where the power was ca. 1.5 mW/cm2, delivering a dose of 10 J/cm2 over 2
h. The laser (Coherent Innova 70C Spectrum) used for irradiation at 514 nm was equipped
with a fibre optic (FT-600-UMT, Ø = 600 μm; Elliot Scientific) to enable delivery of light
to a sample in the NMR probe. The fibre optic was placed 2 mm above the solution in the
NMR tube at which distance the power (ca. 60 mW/cm2) was measured with a Coherent
Fieldmate power meter (OP2-VIS head).
pH Measurements—pH values were measured with an Orion 710A pH meter equipped
with a chloride-free micro-combination electrode (Aldrich) calibrated with Aldrich standard
buffers (pH 4, 7 and 10).
X-ray Crystallography—Diffraction data were collected with Mo-Kα radiation (λ =
0.71073 Å) on a Bruker Smart Apex CCD diffractometer equipped with an Oxford
Cryosystems low-temperature device operating at 150 K. Data were corrected for absorption
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using the program SADABS.53 The crystal structures of 1, 4 and 5 were solved by Patterson
methods (SHELXS54 or DIRDIF55) The structures of 2, 3 and 6 were solved by direct
methods (DIRDIF55 or SIR9256). All structures were refined against F2 using SHELXL54 or
CRYSTALS.57 The crystal structures of 1 – 6 have been deposited in the Cambridge
Crystallographic Data Centre under the accession numbers CCDC 709183,709182, 709184,
709185, 709186 and 709187 respectively, and the cif files are available in the
Supplementary Information. ORTEP diagrams were generated using ORTEP 3v258 and
POV-Ray3.6.59
Computational details—The calculations were generally performed with the Gaussian
03 (G03) program60 employing the DFT method, Becke three-parameter hybrid exchange
functional61 and Lee-Yang-Parr's gradient corrected correlation functional62 (B3LYP). The
LanL2DZ basis set63 and effective core potential were used for the Pt atom and the 6-31G**
basis set64 was used for all other atoms. Geometry optimizations of 1–6 in the ground state
were performed in the gas phase from the x-ray crystallographic structure and the nature of
all stationary points was confirmed by normal mode analysis. The conductor-like polarizable
continuum model method (CPCM)65 with water as solvent was used to calculate the
electronic structure and the excited states of 1–6 in solution. Thirty-two singlet excited states
and the corresponding oscillator strengths were determined with a Time-dependent Density
Functional Theory (TD-DFT)66 calculation. The computational results are summarized in
Tables 3-5 and in the Supplementary Information, where only electronic transitions with an
oscillator strength value (f) higher than 0.01 are reported. The electronic distribution and the
localization of the singlet excited states were visualized using the electron density difference
maps (EDDMs).67 GaussSum 1.0568 was used for EDDMs calculations and for the
electronic spectrum simulation.
Additional geometry optimizations and energy calculations on 4 were performed using the
Amsterdam Density Functional 2007 program (ADF) at the gradient-corrected density
functional theory (DFT) level using BP86 functional in combination with the TZP basis sets.
69
 A small frozen core was used for efficient treatment of the inner atomic shells.
Uncontracted Slater-type orbitals (STOs) were used as basis functions. Relativistic effects
were considered by the zeroth-order regular approximation (ZORA). Electronic excitation
energies were computed with the asymptotically correct XC potential obtained with the
statistical average of (model) orbital potentials (SAOP)70 using scalar relativistic Time-
Dependent Density Functional Theory (TD-DFT) in the ADF program.
Syntheses—Caution! No problems were encountered during this work, however heavy
metal azides are known to be shock sensitive detonators, therefore it is essential that any
platinum azide compound is handled with care.
[Pt(bpy)(N3)2] (1)—[Pt(bpy)Cl2] (98.5 mg) was prepared from K2[PtCl4] and 2,2′-
bipyridine in an 89% yield by the literature method.29 The isolated product was suspended
in DMF (15 mL) and NaN3 (0.152 g, 2.14 mmol) added. After stirring at 298 K in the dark
for 3 d, the volume was reduced to 1–2 mL and H2O added to precipitate the product.
[Pt(bpy)(N3)2] was collected by filtration, washed with water, ethanol and diethyl ether, then
dried under vacuum (93.1 mg, 91.7 %). δH (500 MHz; d6-DMSO; dioxane) 8.91 (d,
H6,6′, 1J5,6 5.7, 2H), 8.57 (d, H3,3′, 1J3,4 8.0, 2H), 8.40 (t, H4,4′, 1J4, 5 7.7, 2H), 7.82 (t,
H5,5′, 2H). Crystals suitable for X-ray structure determination were grown from DMF at 277
K.
[Pt(phen)(N3)2] (2)—The synthesis of [Pt(phen)Cl2] and [Pt(phen)(N3)2] was carried out
by a similar method as described for the corresponding 2,2′-bipyridine complexes. From
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[Pt(phen)Cl2] (100 mg) obtained 2 (85.2 mg, 82.8 %). δH (500 MHz; d6-DMSO, dioxane):
9.20 (d, H2,9, 1J 5.3, 2H), 9.02 (d, H4,7, 1J 8.3, 2H), 8.28 (s, H5,6, 2H), 8.14 (d, H3,8, 2H).
Crystals suitable for X-ray structure determination were grown from DMF at 277 K.
Trans-[Pt(N3)2(py)2] (3)—Trans-[PtCl2(py)2] (166.5 mg) was synthesised by the
literature method30 and converted to the diazido complex 3 (162.6 mg, 94.7 %) by the same
method used for preparation of 1 and 2. δH (500 MHz; d6-acetone, dioxane): 8.86 (dd,
Ho, 1Jo,m 6.6, 2Jo,p 1.7, 4H), 8.12 (tt, Hp, 1Jp,m 7.7, 2H), 7.67 (dd, Hm, 4H). λmax (DMF)/
nm: 273 (ε/M−1 cm−1 14 500) and 328sh (3456). Crystals suitable for X-ray structure
determination were grown from pyridine at 277 K.
Trans, cis-[Pt(bpy)(OAc)2(N3)2] (4)—[Pt(bpy)(N3)2] (10.0 mg, 0.023 mmol) was
suspended in acetic acid (> 99 %, 4 mL) and H2O2 (30 %, 0.23 mmol, 17 μL) added. After
stirring at 298 K for 2 h, all the solvent was removed from the bright orange solution and
acetic anhydride (3 mL) added. After stirring at 298 K for 3 d the solution was again
reduced to dryness and ice-cold H2O added. The yellow solid was collected by filtration,
washed with water, ethanol and ether and dried under vacuum. Crystallisation from a 50:50
acetone/water solution at 277 K gave 4 (7.3 mg, 57.4 %). λmax (H2O)/nm: 250 (ε/M −1
cm−1 19100), 304 (11400) and 315 (9760). δH (500 MHz; d6-acetone, dioxane): 9.30 (d,
H6,6′, 1J5,6 5.9, 2H), 8.69 (d, H3,3′, 1J3,4 7.9, 2H), 8.47 (t, H4,4′, 1J4,5 7.9, 2H), 8.04 (t, H5,5′,
2H), 1.65 (s, CH3, 6H). ESI-MS m/z: 554.1 [M + H]+; 576.0 [M + Na]+. Crystals suitable
for X-ray structure determination were grown from water at 277 K.
Trans, cis-[Pt(phen)(OAc)2(N3)2] (5)—Synthesised from 2 by the oxidation method
outlined for synthesis of 4. Crystals suitable for structure determination were grown from
H2O at 277 K. Yield of 5: 4.7 mg, 42.4 %. UV-vis (H2O)/nm: 272 (ε/M−1 cm−1 17900),
300sh (5840), 337 (1060) and 352 (796). δH (500 MHz; d6-acetone, dioxane): 9.56 (d,
H2,9, 1J 5.5, 2H), 9.06 (d, H4,7, 1J 8.1, 2H), 8.39 (s, H5,6, 2H), 8.36 (d, H3,8, 2H), 1.56 (s,
CH3, 3H). ESI-MS m/z: 578.3 [M + H]+, 600.3 [M + Na]+, 616.4 [M + K]+.
Trans, trans, trans-[Pt(OAc)2(N3)2(py)2] (6)—Synthesised from 3 by the oxidation
method outlined for synthesis of 4. Yield of 6: 6.7 mg, 56.9 %. Crystals suitable for structure
determination were grown from H2O at 277 K. UV-vis (H2O)/nm: 259 (ε/M−1 cm−1 12500)
and 307 (16900). δH (500 MHz; d6-acetone, dioxane): 8.95 (d, Ho, 1J 5.9, 4H), 8.30 (t,
Hp, 1J 7.5, 2H), 7.83 (t, Hm, 4H), 1.92 (s, CH3, 6H). ESI-MS m/z: 556.4 [M + H]+, 578.3 [M
+ Na]+, 594.5 [M + K]+.
Conclusions
Complexes 4–6 are the first reported examples of PtIV-azido complexes which contain
phenanthroline, bipyridine and bispyridine ligands. The x-ray crystal structures of these
complexes show near-octahedral geometry for 4 and 6, with a significant distortion of the
axial groups to give a O–Pt–O angle of 165.12° for complex 5. Irradiation of complexes 4–6
with both UVA (365 nm) and green (514 nm) light results in reduction of the complexes to
PtII species, with release of one or both of the axial acetate ligands. Generation of reactive
aqua species (through azide release) provides promising novel mechanisms for cytotoxic
activity against cancer cells. Irradiation of complexes 4–6 in water is not accompanied by a
large increase in pH as was detected for the previously-reported ammine complex cis, trans,
cis-[Pt(N3)2(OH)2(NH3)2],51 probably due to the reduced lability of the α-diimine ligands
on photoactivation, compared to NH3, in agreement with the mass spectrometric data.
TDDFT calculations enabled us to show the presence of strongly dissociative low energy
transitions for complexes 4–6 since we could identify key orbitals and excited states, their
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relative positions and dependence on the nature of the ligands. In future work we hope to
predict the electronic properties of complexes prior to synthesis. This will allow us to focus
our efforts on compounds which exhibit the most appropriate absorption bands.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Structures of [Pt(bpy)(N3)2] (1), [Pt(phen)(N3)2] (2), trans-[Pt(N3)2(py)2] (3), trans, cis-
[Pt(OAc)2(N3)2(bpy)] (4), trans, cis-[Pt(OAc)2(N3)2(phen)] (5) and trans, trans, trans-
[Pt(OAc)2(N3)2(py)2] (6).
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Figure 2.
ORTEP plots of cis, trans-[Pt(bpy)(N3)2(OH)2] (4), cis, trans-[Pt(phen)(N3)2(OH)2] (5) and
(6) trans, trans, trans-[Pt(N3)2(OH)2(py)2] (6). Non-hydrogen atoms are represented by
Gaussian ellipsoids at the 50% probability level. Hydrogen atoms are shown with arbitrarily
small thermal parameters.
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Figure 3.
Selected orbitals for complexes [Pt(bpy)(N3)2] (1) and [Pt(OAc)2(N3)2(bpy)] (4).
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Figure 4.
Calculated (blue line) and experimental (black line) absorption spectra of 4–6 in H2O. The
excited states are shown as vertical bars with heights equal to the extinction coefficients.
EDDMs of selected singlet transitions, are reported on the right (electron density migrates
from light pink areas to purple ones). Theoretical curves and EDDMs were obtained using
the program GaussSum 1.05.68
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Figure 5.
UV-visible spectra of cis, trans-[Pt(bpy)(N3)2(OH)2] (4), cis, trans-[Pt(phen)(N3)2(OH)2] (5)
and trans, trans, trans-[Pt(N3)2(OH)2(py)2] (6) after UVA irradiation for 0 (–), 1 ( ), 5 ( ),
15 ( ), 30 ( ), 60 ( ) and 120 ( ) min. The arrows denote an increase or decrease of
absorbance with increasing irradiation time.
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Figure 6.
1H NMR spectra showing loss of bound acetate on irradiation for complexes 4–6. The
appearance of free acetate was confirmed by spiking with acetic acid; the very slight change
in chemical shift of the free acetate is due to variation in the pH of the solutions.
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Figure 7.
Electrostatic potential (ESP) surface of complex 2 and 5. ESP surfaces are shown both in
space (with positive and negative regions shown in blue and red, respectively) and mapped
on electron densities (isovalue = 0.004) of the molecule (ESP colour scale is such that δ+ →
δ− in the direction blue → green → yellow → orange → red).
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Table 2
Selected bond lengths (Å) and angles (°) for complexes 4–6. The azide ligands are labelled Pt–Nα–Nβ–Nγ and
the pyridyl nitrogens as NRing.
Bond / Angle
Complex
4 5 6
Pt–N(Ring) 2.033(3) 2.052(4) 2.028(6)
Pt–O 2.020(2) 2.001(3) 2.007(5)
Pt–N(α1) 2.022(3) 2.032(4) 2.049(6)
N(α1) –N(β1) 1.225(5) 1.175(6) 1.224(9)
N(β1) –N(γ1) 1.147(5) 1.154(6) 1.142(10)
Pt–N(α1) –N(β1) 115.0(3) 118.5(4) 114.9(5)
N(α1) –N(β1) –N(γ1) 175.2(5) 173.1(5) 176.0(8)
N(Ring) –Pt–N(Ring) 80.07(17) 81.2(2) 179.994
O–Pt–O 179.18(14) 165.12(19) 179.994
N(α1) –Pt–N(α2) 89.5(2) 96.1(2) 179.994
N(Ring) –Pt–N(α1) 175.25(13) 172.40(16) 89.3(2)
N(Ring) –Pt–N(α2) 95.22(14) 91.40(16) 90.7(2)
N(Ring) –Pt–O 93.82(11) 95.84(13) 95.6(2)
N(Ring2) –Pt–O 85.55(11) 95.44(14) 84.4(2)
N(α1) –Pt–O 95.50(12) 83.17(16) 86.4(2)
N(α2) –Pt–O 85.08(12) 86.90(16) 93.6(2)
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Table 6
Calculated low-energy absorption properties of 4–6.
Tra Composition Energy,eV (nm)
Oscillator
Strength
4
1 HOMO→LUMO (91%) 2.60 (477) 0.0007
2 HOMO–1→LUMO (25%),HOMO→LUMO+1 (66%) 2.80 (442) 0.0001
3 HOMO–1→LUMO (62%)HOMO→LUMO +1 (28%) 3.10 (400) 0.0027
4 HOMO–2→LUMO+1 (17%),HOMO–1→LUMO+1 (76%) 3.25 (381) 0.0019
5
1 HOMO→LUMO (91%) 2.55 (485) 0.0006
2
HOMO–2→LUMO (17%),
HOMO–1→LUMO (−12%),
HOMO→LUMO+1 (64%)
2.77 (447) 0.0001
3
HOMO–2→LUMO (−29%),
HOMO–1→LUMO (36%),
HOMO→LUMO+1 (30%)
3.06 (405) 0.0032
4 HOMO–2→LUMO+1 (49%),HOMO–1→LUMO+1 (−44%) 3.22 (384) 0.0032
6
1 HOMO→LUMO (93%) 2.38 (520) 0.0
2 HOMO–2→LUMO (−10%),HOMO–1→LUMO (85%) 2.91 (427) 0.0021
3 HOMO→LUMO+1 (96%) 3.09 (401) 0.0
4 HOMO–5→LUMO (45%),HOMO–3→LUMO (−41%) 3.27 (379) 0.0
5 HOMO–2→LUMO (82%),HOMO–1→LUMO (10%) 3.29 (377) 0.0068
a
Tr = transition number as obtained in the TDDFT calculation output.
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